Patient characteristics
| . | Discovery cohort (n = 55) . | Validation cohort 1 (n = 55) . | Validation cohort 2 (n = 50) . |
|---|---|---|---|
| Age at transplantation, y | |||
| Mean (range) | 48 (18-65) | 47 (18-66) | 46 (18-68) |
| Recipient/donor sex | |||
| Male/female | 13 (23.6) | 14 (25.5) | 11 (22.0) |
| Other combinations | 42 (76.4) | 41 (74.5) | 39 (78.0) |
| Underlying disease | |||
| Acute leukemia | 30 (54.5) | 40 (72.7) | 31 (62.0) |
| Malignant lymphoma | 5 (9.1) | 5 (9.1) | 6 (12.0) |
| MDS/MPN | 16 (29.1) | 5 (9.1) | 7 (14.0) |
| Aplastic anemia | 3 (5.5) | 5 (9.1) | 1 (2.0) |
| Chronic myeloid leukemia | 1 (1.8) | 0 (0) | 3 (6.0) |
| Other | 0 (0) | 0 (0) | 2 (4.0) |
| Disease risk* | |||
| Low risk | 51 (92.7) | 46 (83.6) | 46 (92.0) |
| High risk | 4 (7.3) | 9 (16.4) | 4 (8.0) |
| Performance status† | |||
| 0-1 | 54 (98.2) | 54 (98.2) | 48 (96.0) |
| 2-4 | 1 (1.8) | 1 (1.8) | 2 (4.0) |
| HCT-CI | |||
| 0-1 | 48 (87.3) | 47 (85.5) | 42 (84.0) |
| ≥2 | 7 (12.7) | 8 (14.5) | 8 (16.0) |
| Stem cell source | |||
| Bone marrow | 34 (61.8) | 31 (56.4) | 25 (50.0) |
| Peripheral blood stem cells | 16 (29.1) | 19 (34.5) | 24 (48.0) |
| Umbilical cord blood | 5 (9.1) | 5 (9.1) | 1 (2.0) |
| HLA | |||
| Match | 31 (56.4) | 25 (45.5) | 30 (60.0) |
| Mismatch | 24 (43.6) | 30 (54.5) | 20 (40.0) |
| Type of donor | |||
| Related | 16 (29.1) | 19 (34.5) | 21 (42.0) |
| Unrelated | 39 (70.9) | 36 (65.5) | 29 (58.0) |
| Conditioning regimen‡ | |||
| Myeloablative | 39 (70.9) | 39 (70.9) | 34 (68.0) |
| Reduced intensity | 16 (29.1) | 16 (29.1) | 16 (32.0) |
| GVHD prophylaxis | |||
| CSA + MTX | 47 (85.5) | 50 (90.9) | 44 (88.0) |
| TAC + MTX | 8 (14.5) | 5 (9.1) | 6(12.0) |
| Use of ATG/alemtuzumab | |||
| No | 49 (89.1) | 44 (80.0) | 37 (74.0) |
| Yes | 6 (10.9) | 11 (20.0) | 13 (26.0) |
| Prior acute GVHD§ | |||
| No | 16 (29.1) | 16 (29.1) | 9 (18.0) |
| Yes | 39 (70.9) | 39 (70.9) | 41 (82.0) |
| Prior cGVHD§ | |||
| No | 29 (52.7) | 33 (60.0) | 23 (46.0) |
| Yes | 26 (47.3) | 22 (40.0) | 27 (54.0) |
| Median days from HSCT to sample acquisition (range) | 179 (133-266) | 178 (168-274) | 181 (168-267) |
| . | Discovery cohort (n = 55) . | Validation cohort 1 (n = 55) . | Validation cohort 2 (n = 50) . |
|---|---|---|---|
| Age at transplantation, y | |||
| Mean (range) | 48 (18-65) | 47 (18-66) | 46 (18-68) |
| Recipient/donor sex | |||
| Male/female | 13 (23.6) | 14 (25.5) | 11 (22.0) |
| Other combinations | 42 (76.4) | 41 (74.5) | 39 (78.0) |
| Underlying disease | |||
| Acute leukemia | 30 (54.5) | 40 (72.7) | 31 (62.0) |
| Malignant lymphoma | 5 (9.1) | 5 (9.1) | 6 (12.0) |
| MDS/MPN | 16 (29.1) | 5 (9.1) | 7 (14.0) |
| Aplastic anemia | 3 (5.5) | 5 (9.1) | 1 (2.0) |
| Chronic myeloid leukemia | 1 (1.8) | 0 (0) | 3 (6.0) |
| Other | 0 (0) | 0 (0) | 2 (4.0) |
| Disease risk* | |||
| Low risk | 51 (92.7) | 46 (83.6) | 46 (92.0) |
| High risk | 4 (7.3) | 9 (16.4) | 4 (8.0) |
| Performance status† | |||
| 0-1 | 54 (98.2) | 54 (98.2) | 48 (96.0) |
| 2-4 | 1 (1.8) | 1 (1.8) | 2 (4.0) |
| HCT-CI | |||
| 0-1 | 48 (87.3) | 47 (85.5) | 42 (84.0) |
| ≥2 | 7 (12.7) | 8 (14.5) | 8 (16.0) |
| Stem cell source | |||
| Bone marrow | 34 (61.8) | 31 (56.4) | 25 (50.0) |
| Peripheral blood stem cells | 16 (29.1) | 19 (34.5) | 24 (48.0) |
| Umbilical cord blood | 5 (9.1) | 5 (9.1) | 1 (2.0) |
| HLA | |||
| Match | 31 (56.4) | 25 (45.5) | 30 (60.0) |
| Mismatch | 24 (43.6) | 30 (54.5) | 20 (40.0) |
| Type of donor | |||
| Related | 16 (29.1) | 19 (34.5) | 21 (42.0) |
| Unrelated | 39 (70.9) | 36 (65.5) | 29 (58.0) |
| Conditioning regimen‡ | |||
| Myeloablative | 39 (70.9) | 39 (70.9) | 34 (68.0) |
| Reduced intensity | 16 (29.1) | 16 (29.1) | 16 (32.0) |
| GVHD prophylaxis | |||
| CSA + MTX | 47 (85.5) | 50 (90.9) | 44 (88.0) |
| TAC + MTX | 8 (14.5) | 5 (9.1) | 6(12.0) |
| Use of ATG/alemtuzumab | |||
| No | 49 (89.1) | 44 (80.0) | 37 (74.0) |
| Yes | 6 (10.9) | 11 (20.0) | 13 (26.0) |
| Prior acute GVHD§ | |||
| No | 16 (29.1) | 16 (29.1) | 9 (18.0) |
| Yes | 39 (70.9) | 39 (70.9) | 41 (82.0) |
| Prior cGVHD§ | |||
| No | 29 (52.7) | 33 (60.0) | 23 (46.0) |
| Yes | 26 (47.3) | 22 (40.0) | 27 (54.0) |
| Median days from HSCT to sample acquisition (range) | 179 (133-266) | 178 (168-274) | 181 (168-267) |
Unless otherwise indicated, data are n (%).
ATG, anti-thymocyte globulin; CSA, cyclosporine; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MTX, methotrexate; TAC, tacrolimus.
Disease risk was categorized as low risk and high risk. High risk was defined as any hematological malignancy in noncomplete remission. Other conditions were considered low risk.
Performance status was evaluated by the Eastern Cooperative Oncology Group scale.
Conditioning intensity was classified based on criteria from the Center for International Blood and Marrow Transplant Research.
History of GVHD at sample acquisition.